COMP <GO>
RMTI vs BCTX // RETURN ON INVESTED CAPITAL (ROIC)
Rockwell Medical Inc. (NASDAQ) VS. BriaCell Therapeutics Corp. (NASDAQ) • 15-METRIC TALLY: RMTI 3
— BCTX 0
■ METRIC PARITY
LAST: $7.31 (0.00%) • MKT CAP: $29.5M
roic
-10.60%
LAST: $3.31 (-5.43%) • MKT CAP: $28.9M
roic
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMTI VS. BCTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMTI | BCTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 16.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -10.60% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -6.80% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -7.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | RMTI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.0 | 31.2 | +9.78 | RMTI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.5M | $28.9M | $558.5K | RMTI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMTI REV | BCTX REV | RMTI GROSS % | BCTX GROSS % | RMTI FCF | BCTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $69.3M | $0 | 16.9% | — | -$659.0K | -$28.2M |
| FY 2024 | $101.5M | $0 | 17.2% | — | $4.2M | -$24.6M |
| FY 2023 | $0 | $0 | — | — | -$9.4M | -$23.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMTI // BETA —
BCTX // BETA —